Literature DB >> 20800376

Renal shielding and dosimetry for patients with severe systemic sclerosis receiving immunoablation with total body irradiation in the scleroderma: cyclophosphamide or transplantation trial.

Oana I Craciunescu1, Beverly A Steffey, Chris R Kelsey, Nicole A Larrier, Cathy J Paarz-Largay, Robert G Prosnitz, Nelson Chao, John Chute, Cristina Gasparetto, Mitchell Horwitz, Gwynn Long, David Rizzieri, Keith M Sullivan.   

Abstract

PURPOSE: To describe renal shielding techniques and dosimetry in delivering total body irradiation (TBI) to patients with severe systemic sclerosis (SSc) enrolled in a hematopoietic stem cell transplant protocol. METHODS AND MATERIALS: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) protocol uses a lymphoablative preparative regimen including 800 cGy TBI delivered in two 200-cGy fractions twice a day before CD34(+) selected autologous hematopoietic stem cell transplantation. Lung and kidney doses are limited to 200 cGy to protect organs damaged by SSc. Kidney block proximity to the spinal cord was investigated, and guidelines were developed for acceptable lumbar area TBI dosing. Information about kidney size and the organ shifts from supine to standing positions were recorded using diagnostic ultrasound (US). Minimum distance between the kidney blocks (dkB) and the lumbar spine region dose was recorded, and in vivo dosimetry was performed at several locations to determine the radiation doses delivered.
RESULTS: Eleven patients were treated at our center with an anteroposterior (AP)/posteroanterior (PA) TBI technique. A 10% to 20% dose inhomogeneity in the lumbar spine region was achieved with a minimum kidney block separation of 4 to 5 cm. The average lumbar spine dose was 179.6 ± 18.1 cGy, with an average dkB of 5.0 ± 1.0 cm. Kidney block shield design was accomplished using a combination of US and noncontrast computerized tomography (CT) or CT imaging alone. The renal US revealed a wide range of kidney displacement from upright to supine positions. Overall, the average in vivo dose for the kidney prescription point was 193.4 ± 5.1 cGy.
CONCLUSIONS: The dose to the kidneys can be attenuated while maintaining a 10% to 20% dose inhomogeneity in the lumbar spine area. Kidneys were localized more accurately using both US and CT imaging. With this technique, renal function has been preserved, and the study continues to enroll patients.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20800376      PMCID: PMC2995833          DOI: 10.1016/j.ijrobp.2010.05.036

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  23 in total

1.  High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes.

Authors:  Peter A McSweeney; Richard A Nash; Keith M Sullivan; Jan Storek; Leslie J Crofford; Roger Dansey; Maureen D Mayes; Kevin T McDonagh; J Lee Nelson; Theodore A Gooley; Leona A Holmberg; C S Chen; Mark H Wener; Katherine Ryan; Julie Sunderhaus; Ken Russell; John Rambharose; Rainer Storb; Daniel E Furst
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

2.  Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.

Authors:  Chitra Hosing; Richard Nash; Peter McSweeney; Shin Mineishi; James Seibold; Linda M Griffith; Howard Shulman; Ellen Goldmuntz; Maureen Mayes; Chirag R Parikh; Leslie Crofford; Lynette Keyes-Elstein; Daniel Furst; Virginia Steen; Keith M Sullivan
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-11       Impact factor: 5.742

3.  Influence of renal shielding on the incidence of late renal dysfunction associated with T-lymphocyte deplete bone marrow transplantation in adult patients.

Authors:  C A Lawton; S W Barber-Derus; K J Murray; E P Cohen; R C Ash; J E Moulder
Journal:  Int J Radiat Oncol Biol Phys       Date:  1992       Impact factor: 7.038

4.  Exaggerated fibrosis in patients with systemic sclerosis (scleroderma) following radiation therapy.

Authors:  M Abu-Shakra; P Lee
Journal:  J Rheumatol       Date:  1993-09       Impact factor: 4.666

5.  Predictors of survival in systemic sclerosis (scleroderma).

Authors:  R D Altman; T A Medsger; D A Bloch; B A Michel
Journal:  Arthritis Rheum       Date:  1991-04

6.  Early undifferentiated connective tissue disease: III. Outcome and prognostic indicators in early scleroderma (systemic sclerosis).

Authors:  K J Bulpitt; P J Clements; P A Lachenbruch; H E Paulus; J B Peter; M S Agopian; J Z Singer; V D Steen; D O Clegg; C M Ziminski; G S Alarcon; M E Luggen; R P Polisson; R F Willkens; J C Reading; H J Williams; J R Ward
Journal:  Ann Intern Med       Date:  1993-04-15       Impact factor: 25.391

Review 7.  Radiation nephropathy.

Authors:  Eric P Cohen; Mike E C Robbins
Journal:  Semin Nephrol       Date:  2003-09       Impact factor: 5.299

8.  Regression of adjuvant-induced arthritis in rats following bone marrow transplantation.

Authors:  D W van Bekkum; E P Bohre; P F Houben; S Knaan-Shanzer
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

9.  Renal insufficiency in patients with hematologic malignancies undergoing total body irradiation and bone marrow transplantation: a prospective assessment.

Authors:  Raymond Miralbell; Gemma Sancho; Sabine Bieri; Ignasi Carrió; Claudine Helg; Salut Brunet; Pierre-Yves Martin; Anna Sureda; Gerard Gomez De Segura; Bernard Chapuis; Montserrat Estorch; Mahmut Ozsahin; Alain Keller
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-03-01       Impact factor: 7.038

10.  Rationale for bone marrow transplantation in the treatment of autoimmune diseases.

Authors:  S Ikehara; R A Good; T Nakamura; K Sekita; S Inoue; M M Oo; E Muso; K Ogawa; Y Hamashima
Journal:  Proc Natl Acad Sci U S A       Date:  1985-04       Impact factor: 11.205

View more
  9 in total

1.  Anti-CD52 antibody-mediated immune ablation with autologous immune recovery for the treatment of refractory juvenile polymyositis.

Authors:  Andreas Reiff; Bracha Shaham; Kenneth I Weinberg; Gay M Crooks; Robertson Parkman
Journal:  J Clin Immunol       Date:  2011-05-04       Impact factor: 8.317

Review 2.  Update on stem cell transplantation for systemic sclerosis: recent trial results.

Authors:  Kamran Naraghi; Jacob M van Laar
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

Review 3.  Stem cell therapy in autoimmune rheumatic diseases: a comprehensive review.

Authors:  Bin Liu; ShangAn Shu; Thomas P Kenny; Christopher Chang; Patrick S C Leung
Journal:  Clin Rev Allergy Immunol       Date:  2014-10       Impact factor: 8.667

4.  Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma.

Authors:  Keith M Sullivan; Ellen A Goldmuntz; Lynette Keyes-Elstein; Peter A McSweeney; Ashley Pinckney; Beverly Welch; Maureen D Mayes; Richard A Nash; Leslie J Crofford; Barry Eggleston; Sharon Castina; Linda M Griffith; Julia S Goldstein; Dennis Wallace; Oana Craciunescu; Dinesh Khanna; Rodney J Folz; Jonathan Goldin; E William St Clair; James R Seibold; Kristine Phillips; Shin Mineishi; Robert W Simms; Karen Ballen; Mark H Wener; George E Georges; Shelly Heimfeld; Chitra Hosing; Stephen Forman; Suzanne Kafaja; Richard M Silver; Leroy Griffing; Jan Storek; Sharon LeClercq; Richard Brasington; Mary E Csuka; Christopher Bredeson; Carolyn Keever-Taylor; Robyn T Domsic; M Bashar Kahaleh; Thomas Medsger; Daniel E Furst
Journal:  N Engl J Med       Date:  2018-01-04       Impact factor: 91.245

5.  Acute kidney injury in patients with systemic sclerosis participating in hematopoietic cell transplantation trials in the United States.

Authors:  Chitra Hosing; Richard Nash; Peter McSweeney; Shin Mineishi; James Seibold; Linda M Griffith; Howard Shulman; Ellen Goldmuntz; Maureen Mayes; Chirag R Parikh; Leslie Crofford; Lynette Keyes-Elstein; Daniel Furst; Virginia Steen; Keith M Sullivan
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-11       Impact factor: 5.742

Review 6.  An update on stem cell transplantation in autoimmune rheumatologic disorders.

Authors:  Sheryl Mascarenhas; Belinda Avalos; Stacy P Ardoin
Journal:  Curr Allergy Asthma Rep       Date:  2012-12       Impact factor: 4.806

Review 7.  Cellular Therapies in Systemic Sclerosis: Recent Progress.

Authors:  Femke C C van Rhijn-Brouwer; Hendrik Gremmels; Joost O Fledderus; Timothy R D Radstake; Marianne C Verhaar; Jacob M van Laar
Journal:  Curr Rheumatol Rep       Date:  2016-02       Impact factor: 4.592

8.  Effect of total body irradiation lung block parameters on lung doses using three-dimensional dosimetry.

Authors:  Samuel M H Luk; Kent Wallner; Mallory C Glenn; Ralph Ermoian; Mark H Phillips; Yolanda D Tseng; Minsun Kim
Journal:  J Appl Clin Med Phys       Date:  2022-01-05       Impact factor: 2.102

Review 9.  Review: Hematopoietic Stem Cell Transplantation for Scleroderma: Effective Immunomodulatory Therapy for Patients With Pulmonary Involvement.

Authors:  Keith M Sullivan; Ankoor Shah; Stefanie Sarantopoulos; Daniel E Furst
Journal:  Arthritis Rheumatol       Date:  2016-10       Impact factor: 10.995

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.